Were Analysts Bullish Quest Diagnostics Incorporated (NYSE:DGX) This Week?

Quest Diagnostics Incorporated (NYSE:DGX) Logo
Investors sentiment decreased to 1.12 in 2019 Q2. Its down 0.10, from 1.22 in 2019Q1. It turned negative, as 32 investors sold Quest Diagnostics Incorporated shares while 169 reduced holdings. 59 funds opened positions while 166 raised stakes. 115.81 million shares or 0.76% less from 116.69 million shares in 2019Q1 were reported.
Needham Management Lc has 0.18% invested in Quest Diagnostics Incorporated (NYSE:DGX) for 5,250 shares. National Pension Ser invested in 174,909 shares or 0.06% of the stock. Cullen Frost Bankers holds 0% or 656 shares. Moreover, Yorktown Research Inc has 0.19% invested in Quest Diagnostics Incorporated (NYSE:DGX). Klingenstein Fields & Ltd Liability Com holds 0.02% in Quest Diagnostics Incorporated (NYSE:DGX) or 4,485 shares. Wesbanco Savings Bank has invested 0.02% in Quest Diagnostics Incorporated (NYSE:DGX). Bank Of Ny Mellon Corporation reported 1.40M shares. Geode Capital Limited holds 0.05% in Quest Diagnostics Incorporated (NYSE:DGX) or 2.09 million shares. Argi Investment Services Limited Co has invested 0.05% in Quest Diagnostics Incorporated (NYSE:DGX). Adirondack Tru Co has invested 0% in Quest Diagnostics Incorporated (NYSE:DGX). Carroll Inc holds 200 shares. Andra Ap owns 0.18% invested in Quest Diagnostics Incorporated (NYSE:DGX) for 61,700 shares. 2.21M are held by Bancshares Of America De. Wms Prns Limited Liability Co reported 2,367 shares. Psagot House Ltd accumulated 1,780 shares.

Quest Diagnostics Incorporated (NYSE:DGX) Ratings Coverage

Among 6 analysts covering Quest Diagnostics (NYSE:DGX), 2 have Buy rating, 1 Sell and 3 Hold. Therefore 33% are positive. Quest Diagnostics has $12100 highest and $8500 lowest target. $105.50’s average target is 1.05% above currents $104.4 stock price. Quest Diagnostics had 15 analyst reports since March 16, 2019 according to SRatingsIntel. The stock has “Neutral” rating by JP Morgan on Wednesday, July 24. The stock has “Overweight” rating by Morgan Stanley on Thursday, April 25. Credit Suisse maintained the shares of DGX in report on Wednesday, July 24 with “Neutral” rating. The company was maintained on Wednesday, April 24 by Canaccord Genuity. Morgan Stanley maintained Quest Diagnostics Incorporated (NYSE:DGX) on Wednesday, July 24 with “Overweight” rating. UBS maintained Quest Diagnostics Incorporated (NYSE:DGX) rating on Wednesday, April 24. UBS has “Neutral” rating and $9900 target. Canaccord Genuity maintained Quest Diagnostics Incorporated (NYSE:DGX) rating on Wednesday, July 24. Canaccord Genuity has “Buy” rating and $11200 target. The firm earned “Overweight” rating on Friday, August 23 by Morgan Stanley. As per Monday, July 15, the company rating was downgraded by Goldman Sachs. Below is a list of Quest Diagnostics Incorporated (NYSE:DGX) latest ratings and price target changes.

23/08/2019 Broker: Morgan Stanley Rating: Overweight Old Target: $111.0000 New Target: $121.0000 Maintain
24/07/2019 Broker: JP Morgan Rating: Neutral Old Target: $100.0000 New Target: $111.0000 Maintain
24/07/2019 Broker: Morgan Stanley Rating: Overweight Old Target: $104.0000 New Target: $111.0000 Maintain
24/07/2019 Broker: Canaccord Genuity Rating: Buy Old Target: $108.0000 New Target: $112.0000 Maintain
24/07/2019 Broker: Credit Suisse Rating: Neutral Old Target: $99.0000 New Target: $105.0000 Maintain
15/07/2019 Broker: Goldman Sachs Old Rating: Neutral New Rating: Sell Old Target: $90.0000 New Target: $85.0000 Downgrade
25/06/2019 Broker: Deutsche Bank Rating: Hold Maintain
10/05/2019 Broker: BidaskScore Rating: Sell Upgrade
25/04/2019 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $98.0000 New Target: $104.0000 Maintain
24/04/2019 Broker: UBS Rating: Neutral Old Target: $91.0000 New Target: $99.0000 Maintain

The stock decreased 0.54% or $0.57 during the last trading session, reaching $104.4. About 795,229 shares traded. Quest Diagnostics Incorporated (NYSE:DGX) has declined 4.62% since September 13, 2018 and is downtrending. It has underperformed by 4.62% the S&P500.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company has market cap of $14.06 billion. The companyÂ’s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, gene and esoteric testing, and drugs-of-abuse testing, as well as anatomic pathology services, and related services and insights. It has a 19.69 P/E ratio. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum, and Care360 brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, and phlebotomists in physician offices.

More notable recent Quest Diagnostics Incorporated (NYSE:DGX) news were published by: Finance.Yahoo.com which released: “Is Quest Diagnostics Incorporated (NYSE:DGX) A Smart Pick For Income Investors? – Yahoo Finance” on June 18, 2019, also Finance.Yahoo.com with their article: “Is Quest Diagnostics Incorporated (NYSE:DGX) Better Than Average At Deploying Capital? – Yahoo Finance” published on July 24, 2019, Finance.Yahoo.com published: “Is Quest Diagnostics Incorporated’s (NYSE:DGX) CEO Salary Justified? – Yahoo Finance” on May 31, 2019. More interesting news about Quest Diagnostics Incorporated (NYSE:DGX) were released by: Finance.Yahoo.com and their article: “Can You Imagine How Quest Diagnostics’s (NYSE:DGX) Shareholders Feel About The 62% Share Price Increase? – Yahoo Finance” published on August 13, 2019 as well as Finance.Yahoo.com‘s news article titled: “Is It Too Late To Consider Buying Quest Diagnostics Incorporated (NYSE:DGX)? – Yahoo Finance” with publication date: August 30, 2019.

Quest Diagnostics Incorporated (NYSE:DGX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.